Population-level evaluation of complications after catheter ablation in patients with atrial fibrillation and heart failure.
adverse events
atrial fibrillation
catheter ablation
heart failure
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
16
08
2019
revised:
11
09
2019
accepted:
26
09
2019
pubmed:
4
10
2019
medline:
21
10
2020
entrez:
4
10
2019
Statut:
ppublish
Résumé
Catheter ablation (CA) has been increasingly used to treat atrial fibrillation (AF) in patients with heart failure (HF), however, its safety at the population-level has not yet been evaluated. To assess the safety of CA in AF-HF patients, the frequency and potential risk factors for adverse events (AEs) within 30 days post-CA were determined. A population-based cohort of AF-HF patients who underwent CA in Quebec, Canada (2000-2017) was constructed using administrative databases. Major AEs included all-cause mortality, cerebrovascular accident (CVA), pericardial effusion requiring drainage (PERD), vascular AEs, hemorrhage/hematoma, and pulmonary embolism. Univariate logistic regression models were employed to assess potential risk factors for major AEs. Of 700 AF-HF patients who underwent CA (median age 64.5 years [interquartile range, IQR, 56.2-71.0], 22.0% female, and median CHA CA performed in the AF-HF population portends a relatively low incidence of major AEs. A larger study is required to determine whether certain patient factors are independently associated with a higher risk of post-CA AEs.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2678-2685Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : Clinical Research Scholars Award to Vidal Essebag
Pays : International
Organisme : Fonds de Recherche du Québec - Santé
ID : Doctoral Training Award to Michelle Samuel
Pays : International
Organisme : McGill University -
ID : James McGill Chair to Louise Pilote (Medicine)
Pays : International
Organisme : McGill University -
ID : James McGill Chair to Michal Abrahamowicz (Biostatistics)
Pays : International
Organisme : CIHR
ID : (133717)
Pays : Canada
Organisme : CIHR
ID : (133717)
Pays : Canada
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Samuel M, Almohammadi M, Tsadok MA, et al. Population-based evaluation of major adverse events after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2017;3:1425-1433.
Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36:307-314a.
Rabah A, Wazni O. Atrial fibrillation in heart failure: catheter and surgical interventional therapies. Heart Fail Rev. 2014;19:325-330.
Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4:S61-S64.
Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
Bertaglia E, Zoppo F, Tondo C, et al. Early complications of pulmonary vein catheter ablation for atrial fibrillation: a multicenter prospective registry on procedural safety. Heart Rhythm. 2007;4:1265-1271.
Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013;128:2104-2112.
Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA. 2019;321:1261-1274.
Tripathi B, Arora S, Kumar V, et al. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from Nationwide Inpatient Sample database (2011-2014). J Cardiovasc Electrophysiol. 2018;29:715-724.
Dagres N, Hindricks G, Kottkamp H, et al. Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol. 2009;20:1014-1019.
Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.
Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100-1105.
Hoyt H, Bhonsale A, Chilukuri K, et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm. 2011;8:1869-1874.
Baman TS, Jongnarangsin K, Chugh A, et al. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:626-631.
Aldhoon B, Wichterle D, Peichl P, Čihák R, Kautzner J. Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography. Europace. 2013;15:24-32.
Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol. 2008;19:627-631.
Lee G, Sparks PB, Morton JB, et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol. 2011;22:163-168.
Leong-Sit P, Zado E, Callans DJ, et al. Efficacy and risk of atrial fibrillation ablation before 45 years of age. Circ Arrhythm Electrophysiol. 2010;3:452-457.
Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol. 2013;6:1082-1088.
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-427.
Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637-1644.
AlTurki A, Proietti R, Dawas A, Alturki H, Huynh T, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019;19:18.
Skanes AC, Tang ASL. Atrial fibrillation and heart failure: untangling a modern Gordian knot. Can J Cardiol. 2018;34:1437-1448.
Briceño DF, Markman TM, Lupercio F, et al. Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018;53:19-29.
Ma Y, Bai F, Qin F, et al. Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18:165.
Joza J, Samuel M, Jackevicius CA, et al. Long-term risk of stroke and bleeding post-atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2018;29:1355-1362.
Samuel M, Avgil Tsadok M, Joza J, et al. Catheter ablation for the treatment of atrial fibrillation is associated with a reduction in health care resource utilization. J Cardiovasc Electrophysiol. 2017;28:733-741.
Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):129-140.
Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182-188.
Mardigyan V, Verma A, Birnie D, et al. Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol. 2013;29:219-223.
MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97:740-747.
Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction. J Am Coll Cardiol. 2017;70:1949-1961.
Jones DG, Haldar SK, Donovan J, et al. Biomarkers in persistent AF and heart failure: Impact of catheter ablation compared with rate control. Pacing Clin Electrophysiol. 2016;39:926-934.
Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778-1785.
Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7:31-38.
Steinbeck G, Sinner MF, Lutz M, Müller-Nurasyid M, Kääb S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J. 2018;39:4020-4029.
Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5(3):e002197.
Durheim MT, Cyr DD, Lopes RD, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. Int J Cardiol. 2016;202:589-594.
Dzeshka MS, Lip GYH. Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation. Thromb Res. 2014;134:217-218.